<p>药明康德公司（NASDAQ:EXEL - 获取免费报告）在周三的交易中下跌了 5.6%。该公司的股价最低曾达到 34.39 美元，最后交易价为 34.38 美元。在交易过程中，约有 399,288 股易手，较日均交易量 2,414,278 股下降了 83%。该股票此前收盘价为 36.43 美元。</p>
<h2>分析师评级变动</h2>
<ul>
<li>如果有的话，3 只适合软着陆的股票</li>
</ul>
<p>几家研究公司最近对 EXEL 发布了报告。Stephens 将药明康德的目标股价从 23.00 美元上调至 29.00 美元，并在 10 月 30 日的研究报告中给予该股票 “持平” 评级。高盛集团在 10 月 15 日的研究报告中将药明康德的评级上调至 “强烈卖出”。富国银行在 10 月 30 日的研究报告中将药明康德的目标价从 32.00 美元上调至 36.00 美元，并给予公司 “超配” 评级。摩根士丹利在 10 月 11 日的研究报告中将药明康德的目标价从 26.00 美元上调至 28.00 美元，并给予公司 “持平” 评级。最后，Oppenheimer 将药明康德的评级从 “跑赢大盘” 下调至 “市场表现”，并在周五的研究报告中将公司的目标价从 41.00 美元下调至 33.00 美元。一位股票研究分析师给予该股票 “卖出” 评级，八位分析师给予 “持有” 评级，十位分析师给予 “买入” 评级，还有一位分析师给予 “强烈买入” 评级。根据 MarketBeat.com 的数据，药明康德目前的平均评级为 “适度买入”，平均目标价为 35.00 美元。</p>
<p><strong>查看我们对 EXEL 的最新分析</strong></p>
<h2>药明康德股票下跌 5.1%</h2>
<ul>
<li>3 只强劲的生物科技表现者，值得关注，随着行业接近突破</li>
</ul>
<p>该公司的 50 日简单移动平均线为 34.91 美元，200 日简单移动平均线为 29.64 美元。公司市值为 92.5 亿美元，市盈率为 20.76，市盈增长比率为 0.72，贝塔值为 0.53。</p>
<p>药明康德（NASDAQ:EXEL - 获取免费报告）最近在 10 月 29 日发布了其财报。这家生物技术公司报告本季度每股收益为 0.40 美元，超出市场共识预期的 0.36 美元，超出幅度为 0.04 美元。药明康德的股本回报率为 20.99%，净利润率为 22.43%。该公司本季度的收入为 5.395 亿美元，而分析师预期为 4.9031 亿美元。去年同期，该公司每股收益为 0.10 美元。与去年同期相比，该公司的收入增长了 14.3%。分析师预计药明康德将在本财年发布 1.74 美元的每股收益。</p>
<h2>药明康德的内部活动</h2>
<ul>
<li>现在投资的 7 只最佳癌症股票</li>
</ul>
<p>在其他药明康德的新闻中，执行副总裁 Dana Aftab 在 10 月 30 日的交易中出售了 1,162 股公司股票。股票以平均价格 31.40 美元出售，总价值为 36,486.80 美元。出售后，该执行副总裁现在直接持有 498,945 股公司股票，价值约为 15,666,873 美元。此次交易使其持股比例减少了 0.23%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过此链接访问。此外，执行副总裁 Jeffrey Hessekiel 在 11 月 29 日的交易中出售了 60,000 股药明康德股票。该股票以平均价格 36.67 美元出售，总交易额为 2,200,200.00 美元。交易完成后，该执行副总裁现在直接持有 486,059 股公司股票，价值为 17,823,783.53 美元。这代表其持股比例减少了 10.99%。该出售的披露信息可在此找到。过去一个季度，内部人士已出售 314,736 股公司股票，价值 10,849,110 美元。目前，2.85% 的股票由公司内部人士持有。</p>
<h2>机构投资者对药明康德的看法</h2>
<p>机构投资者和对冲基金最近调整了对该股票的持有。USA Financial Formulas 在第四季度获得了药明康德的新头寸，价值 32,000 美元。V Square Quantitative Management LLC 在第三季度购买了药明康德的新头寸，价值约 30,000 美元。UMB Bank n.a.在第四季度将其在药明康德的持股增加了 68.4%。UMB Bank n.a.目前持有 1,361 股该生物技术公司的股票，价值 45,000 美元，此前在该期间内购买了 553 股。Brooklyn Investment Group 在第三季度购买了药明康德的新股份，价值 42,000 美元。最后，MassMutual Private Wealth &amp; Trust FSB 在第四季度将其在药明康德的持股增加了 18.1%。MassMutual Private Wealth &amp; Trust FSB 目前持有 1,890 股该生物技术公司的股票，价值 63,000 美元，此前在该期间内购买了 290 股。85.27% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于药明康德</h2>
<p>（获取免费报告）</p>
<p>药明康德公司是一家肿瘤学公司，专注于在美国发现、开发和商业化用于治疗难治性癌症的新药物。该公司提供 CABOMETYX 片剂，用于治疗接受过抗血管生成治疗的晚期肾细胞癌患者；以及 COMETRIQ 胶囊，用于治疗进展性和转移性髓样甲状腺癌。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过药明康德</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>为什么能源转移股票可能在 2025 年飙升至新高</li>
<li>如何逐步购买便宜股票</li>
<li>3 只适合长期增长的买入持有股票</li>
<li>基础材料股票投资</li>
<li>尽管短期风险，Freeport McMoran 值得关注</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在伊克力西斯吗？</h2>
<p>在你考虑伊克力西斯之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而伊克力西斯并不在名单上。</p>
<p>虽然伊克力西斯目前在分析师中被评为 “持有”，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

伊克力西斯

<p>Exelixis, Inc.（纳斯达克代码：EXEL）在交易中股价下跌 5.6%，至 34.38 美元，成交量显著下降。分析师的评级不一，价格目标范围从 23 美元到 41 美元不等。该公司报告的季度每股收益为 0.40 美元，超出预期，收入为 5.395 亿美元，同比增长 14.3%。内部交易活动包括高管的股票出售，机构投资者最近也调整了持股。Exelixis 的平均评级为 “适度买入”，价格目标为 35.00 美元</p>

<p>Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) was down 5.6% during trading on Wednesday . The company traded as low as $34.39 and last traded at $34.38. Approximately 399,288 shares changed hands during trading, a decline of 83% from the average daily volume of 2,414,278 shares. The stock had previously closed at $36.43.</p>
<div class="lb-trans"><p>药明康德公司（NASDAQ:EXEL - 获取免费报告）在周三的交易中下跌了 5.6%。该公司的股价最低曾达到 34.39 美元，最后交易价为 34.38 美元。在交易过程中，约有 399,288 股易手，较日均交易量 2,414,278 股下降了 83%。该股票此前收盘价为 36.43 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>3 Stocks to Buy for a Soft Landing, If There Is One</li>
</ul>
<div class="lb-trans"><ul>
<li>如果有的话，3 只适合软着陆的股票</li>
</ul>
</div><p>Several research firms recently issued reports on EXEL. Stephens lifted their price target on shares of Exelixis from $23.00 to $29.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Wednesday, October 30th. The Goldman Sachs Group upgraded Exelixis to a &#34;strong sell&#34; rating in a research note on Tuesday, October 15th. Wells Fargo &amp; Company raised their price objective on Exelixis from $32.00 to $36.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, October 30th. Morgan Stanley upped their target price on Exelixis from $26.00 to $28.00 and gave the company an &#34;equal weight&#34; rating in a research report on Friday, October 11th. Finally, Oppenheimer cut Exelixis from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and reduced their target price for the company from $41.00 to $33.00 in a research note on Friday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Exelixis presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $35.00.</p>
<div class="lb-trans"><p>几家研究公司最近对 EXEL 发布了报告。Stephens 将药明康德的目标股价从 23.00 美元上调至 29.00 美元，并在 10 月 30 日的研究报告中给予该股票 “持平” 评级。高盛集团在 10 月 15 日的研究报告中将药明康德的评级上调至 “强烈卖出”。富国银行在 10 月 30 日的研究报告中将药明康德的目标价从 32.00 美元上调至 36.00 美元，并给予公司 “超配” 评级。摩根士丹利在 10 月 11 日的研究报告中将药明康德的目标价从 26.00 美元上调至 28.00 美元，并给予公司 “持平” 评级。最后，Oppenheimer 将药明康德的评级从 “跑赢大盘” 下调至 “市场表现”，并在周五的研究报告中将公司的目标价从 41.00 美元下调至 33.00 美元。一位股票研究分析师给予该股票 “卖出” 评级，八位分析师给予 “持有” 评级，十位分析师给予 “买入” 评级，还有一位分析师给予 “强烈买入” 评级。根据 MarketBeat.com 的数据，药明康德目前的平均评级为 “适度买入”，平均目标价为 35.00 美元。</p>
</div><p><strong>View Our Latest Analysis on EXEL</strong></p>
<div class="lb-trans"><p><strong>查看我们对 EXEL 的最新分析</strong></p>
</div><h2>Exelixis Stock Down 5.1 %</h2>
<div class="lb-trans"><h2>药明康德股票下跌 5.1%</h2>
</div><ul>
<li>3 Strong Biotech Performers To Watch As Sector Nears Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只强劲的生物科技表现者，值得关注，随着行业接近突破</li>
</ul>
</div><p>The firm's 50 day simple moving average is $34.91 and its 200 day simple moving average is $29.64. The company has a market cap of $9.25 billion, a price-to-earnings ratio of 20.76, a price-to-earnings-growth ratio of 0.72 and a beta of 0.53.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 34.91 美元，200 日简单移动平均线为 29.64 美元。公司市值为 92.5 亿美元，市盈率为 20.76，市盈增长比率为 0.72，贝塔值为 0.53。</p>
</div><p>Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm had revenue of $539.50 million for the quarter, compared to analysts' expectations of $490.31 million. During the same period last year, the firm earned $0.10 EPS. The firm's revenue was up 14.3% compared to the same quarter last year. Analysts anticipate that Exelixis, Inc. will post 1.74 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:EXEL - 获取免费报告）最近在 10 月 29 日发布了其财报。这家生物技术公司报告本季度每股收益为 0.40 美元，超出市场共识预期的 0.36 美元，超出幅度为 0.04 美元。药明康德的股本回报率为 20.99%，净利润率为 22.43%。该公司本季度的收入为 5.395 亿美元，而分析师预期为 4.9031 亿美元。去年同期，该公司每股收益为 0.10 美元。与去年同期相比，该公司的收入增长了 14.3%。分析师预计药明康德将在本财年发布 1.74 美元的每股收益。</p>
</div><h2>Insider Activity at Exelixis</h2>
<div class="lb-trans"><h2>药明康德的内部活动</h2>
</div><ul>
<li>7 Best Cancer Stocks to Invest in Now</li>
</ul>
<div class="lb-trans"><ul>
<li>现在投资的 7 只最佳癌症股票</li>
</ul>
</div><p>In other Exelixis news, EVP Dana Aftab sold 1,162 shares of the business's stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total value of $36,486.80. Following the sale, the executive vice president now directly owns 498,945 shares in the company, valued at approximately $15,666,873. The trade was a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the transaction, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. This represents a 10.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 314,736 shares of company stock worth $10,849,110 over the last quarter. 2.85% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他药明康德的新闻中，执行副总裁 Dana Aftab 在 10 月 30 日的交易中出售了 1,162 股公司股票。股票以平均价格 31.40 美元出售，总价值为 36,486.80 美元。出售后，该执行副总裁现在直接持有 498,945 股公司股票，价值约为 15,666,873 美元。此次交易使其持股比例减少了 0.23%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过此链接访问。此外，执行副总裁 Jeffrey Hessekiel 在 11 月 29 日的交易中出售了 60,000 股药明康德股票。该股票以平均价格 36.67 美元出售，总交易额为 2,200,200.00 美元。交易完成后，该执行副总裁现在直接持有 486,059 股公司股票，价值为 17,823,783.53 美元。这代表其持股比例减少了 10.99%。该出售的披露信息可在此找到。过去一个季度，内部人士已出售 314,736 股公司股票，价值 10,849,110 美元。目前，2.85% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Exelixis</h2>
<div class="lb-trans"><h2>机构投资者对药明康德的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. USA Financial Formulas acquired a new position in shares of Exelixis in the 4th quarter valued at $32,000. V Square Quantitative Management LLC purchased a new position in shares of Exelixis in the third quarter worth approximately $30,000. UMB Bank n.a. boosted its stake in Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 553 shares during the period. Brooklyn Investment Group purchased a new stake in shares of Exelixis in the third quarter valued at $42,000. Finally, MassMutual Private Wealth &amp; Trust FSB raised its position in Exelixis by 18.1% during the fourth quarter. MassMutual Private Wealth &amp; Trust FSB now owns 1,890 shares of the biotechnology company's stock valued at $63,000 after buying an additional 290 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该股票的持有。USA Financial Formulas 在第四季度获得了药明康德的新头寸，价值 32,000 美元。V Square Quantitative Management LLC 在第三季度购买了药明康德的新头寸，价值约 30,000 美元。UMB Bank n.a.在第四季度将其在药明康德的持股增加了 68.4%。UMB Bank n.a.目前持有 1,361 股该生物技术公司的股票，价值 45,000 美元，此前在该期间内购买了 553 股。Brooklyn Investment Group 在第三季度购买了药明康德的新股份，价值 42,000 美元。最后，MassMutual Private Wealth &amp; Trust FSB 在第四季度将其在药明康德的持股增加了 18.1%。MassMutual Private Wealth &amp; Trust FSB 目前持有 1,890 股该生物技术公司的股票，价值 63,000 美元，此前在该期间内购买了 290 股。85.27% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Exelixis</h2>
<div class="lb-trans"><h2>关于药明康德</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.</p>
<div class="lb-trans"><p>药明康德公司是一家肿瘤学公司，专注于在美国发现、开发和商业化用于治疗难治性癌症的新药物。该公司提供 CABOMETYX 片剂，用于治疗接受过抗血管生成治疗的晚期肾细胞癌患者；以及 COMETRIQ 胶囊，用于治疗进展性和转移性髓样甲状腺癌。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Exelixis</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>Why Energy Transfer Stock Could Soar to New Highs in 2025</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>3 Buy-and-Hold Stocks for Long-Term Growth</li>
<li>Basic Materials Stocks Investing</li>
<li>Despite Short-Term Risks Freeport McMoran Worth a Look</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过药明康德</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>为什么能源转移股票可能在 2025 年飙升至新高</li>
<li>如何逐步购买便宜股票</li>
<li>3 只适合长期增长的买入持有股票</li>
<li>基础材料股票投资</li>
<li>尽管短期风险，Freeport McMoran 值得关注</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Exelixis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在伊克力西斯吗？</h2>
</div><p>Before you consider Exelixis, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑伊克力西斯之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而伊克力西斯并不在名单上。</p>
</div><p>While Exelixis currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然伊克力西斯目前在分析师中被评为 “持有”，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

伊克力西斯（NASDAQ:EXEL）股价下跌 5.6% 的原因如下